Related references
Note: Only part of the references are listed.How to: Clostridioides difficile infection in children
Marcela Krutova et al.
CLINICAL MICROBIOLOGY AND INFECTION (2022)
European Society of Clinical Microbiology and Infectious Diseases: 2021 update on the treatment guidance document for Clostridioides difficile infection in adults
Joffrey van Prehn et al.
CLINICAL MICROBIOLOGY AND INFECTION (2021)
ACG Clinical Guidelines: Prevention, Diagnosis, and Treatment of Clostridioides difficile Infections
Colleen R. Kelly et al.
AMERICAN JOURNAL OF GASTROENTEROLOGY (2021)
Clinical Practice Guideline by the Infectious Diseases Society of America (IDSA) and Society for Healthcare Epidemiology of America (SHEA): 2021 Focused Update Guidelines on Management of Clostridioides difficile Infection in Adults
Stuart Johnson et al.
CLINICAL INFECTIOUS DISEASES (2021)
Safety and Efficacy of Fidaxomicin and Vancomycin in Children and Adolescents with Clostridioides (Clostridium) difficile Infection: A Phase 3, Multicenter, Randomized, Single-blind Clinical Trial (SUNSHINE)
Joshua Wolf et al.
CLINICAL INFECTIOUS DISEASES (2020)
Bezlotoxumab for prevention of Clostridium difficile infection recurrence: Distinguishing relapse from reinfection with whole genome sequencing
Zhen Zeng et al.
ANAEROBE (2020)
Efficacy of Bezlotoxumab in Participants Receiving Metronidazole, Vancomycin, or Fidaxomicin for Treatment of Clostridioides (Clostridium) difficile Infection
Erik R. Dubberke et al.
OPEN FORUM INFECTIOUS DISEASES (2020)
Comparison of different modes of antibiotic delivery on gut microbiota depletion efficiency and body composition in mouse
Pauline Tirelle et al.
BMC MICROBIOLOGY (2020)
Clostridium difficile infection trials: what is the primary endpoint?
Benoit Guery
LANCET INFECTIOUS DISEASES (2019)
Cadazolid for the treatment of Clostridium difficile infection: results of two double-blind, placebo-controlled, non-inferiority, randomised phase 3 trials
Dale N. Gerding et al.
LANCET INFECTIOUS DISEASES (2019)
Clinical Practice Guidelines for Clostridium difficile Infection in Adults and Children: 2017 Update by the Infectious Diseases Society of America (IDSA) and Society for Healthcare Epidemiology of America (SHEA)
L. Clifford McDonald et al.
CLINICAL INFECTIOUS DISEASES (2018)
Efficacy and safety of fidaxomicin for the treatment of Clostridioides (Clostridium) difficile infection in a randomized, double-blind, comparative Phase III study in Japan
Hiroshige Mikamo et al.
JOURNAL OF INFECTION AND CHEMOTHERAPY (2018)
Extended-pulsed fidaxomicin versus vancomycin for Clostridium difficile infection in patients 60 years and older (EXTEND): a randomised, controlled, open-label, phase 3b/4 trial
Benoit Guery et al.
LANCET INFECTIOUS DISEASES (2018)
Surotomycin versus vancomycin in adults with Clostridium difficile infection: primary clinical outcomes from the second pivotal, randomized, double-blind, Phase 3 trial
P. Daley et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2017)
Bezlotoxumab for Prevention of Recurrent Clostridium difficile Infection
M. H. Wilcox et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Primary Outcomes From a Phase 3, Randomized, Double-Blind, Active-Controlled Trial of Surotomycin in Subjects With Clostridium difficile Infection
Vicente Boix et al.
OPEN FORUM INFECTIOUS DISEASES (2017)
Stool consistency is strongly associated with gut microbiota richness and composition, enterotypes and bacterial growth rates
Doris Vandeputte et al.
GUT (2016)
Administration of Spores of Nontoxigenic Clostridium difficile Strain M3 for Prevention of Recurrent C difficile Infection A Randomized Clinical Trial
Dale N. Gerding et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2015)
Lack of Evidence for an Unmet Need to Treat Clostridium difficile Infection in Infants Aged <2 Years: Expert Recommendations on How to Address This Issue
Saul N. Faust et al.
CLINICAL INFECTIOUS DISEASES (2015)
Vancomycin, Metronidazole, or Tolevamer for Clostridium difficile Infection: Results From Two Multinational, Randomized, Controlled Trials
Stuart Johnson et al.
CLINICAL INFECTIOUS DISEASES (2014)
Markers of Intestinal Inflammation, Not Bacterial Burden, Correlate With Clinical Outcomes in Clostridium difficile Infection
Rana E. El Feghaly et al.
CLINICAL INFECTIOUS DISEASES (2013)
Defining the Vulnerable Period for Re-Establishment of Clostridium difficile Colonization after Treatment of C. difficile Infection with Oral Vancomycin or Metronidazole
Turki Abujamel et al.
PLOS ONE (2013)
Relapse Versus Reinfection: Recurrent Clostridium difficile Infection Following Treatment With Fidaxomicin or Vancomycin
Iris Figueroa et al.
CLINICAL INFECTIOUS DISEASES (2012)
Fidaxomicin versus vancomycin for infection with Clostridium difficile in Europe, Canada, and the USA: a double-blind, non-inferiority, randomised controlled trial
Oliver A. Cornely et al.
LANCET INFECTIOUS DISEASES (2012)
Clostridium difficile Infection in Children: Current State and Unanswered Questions
Pranita D. Tamma et al.
JOURNAL OF THE PEDIATRIC INFECTIOUS DISEASES SOCIETY (2012)
Fidaxomicin versus Vancomycin for Clostridium difficile Infection
Thomas J. Louie et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Role of Colonic Short-Chain Fatty Acid Transport in Diarrhea
Henry J. Binder
ANNUAL REVIEW OF PHYSIOLOGY (2010)
Fulminant Clostridium difficile Colitis Patterns of Care and Predictors of Mortality
Elizabeth A. Sailhamer et al.
ARCHIVES OF SURGERY (2009)
Clinical recognition and diagnosis of Clostridium difficile infection
John G. Bartlett et al.
CLINICAL INFECTIOUS DISEASES (2008)
A comparison of vancomycin and metronidazole for the treatment of Clostridium difficile -: Associated diarrhea, stratified by disease severity
Fred A. Zar et al.
CLINICAL INFECTIOUS DISEASES (2007)
Nitazoxanide for the treatment of Clostridium difficile colitis
Daniel M. Musher et al.
CLINICAL INFECTIOUS DISEASES (2006)
Fulminant Clostridium difficile: An underappreciated and increasing cause of death and complications
RM Dallal et al.
ANNALS OF SURGERY (2002)
Share Paper
